Literature DB >> 30311004

Immunotherapy for Brain Tumors.

Lan B Hoang-Minh1, Duane A Mitchell2.   

Abstract

OPINION STATEMENT: Despite aggressive surgery, radiation, and systemic chemotherapy, the prognosis for patients diagnosed with malignant brain tumors remains extremely poor, and standard treatments carry significant risks for long-term neurocognitive deficits. There is a clear and urgent need for the development of more effective treatments that will add minimal toxicity to standard therapies for invasive brain cancers. Cancer immunotherapy is a treatment modality that holds promise for the delivery of tumor-specific cytotoxicity, with the potential to eliminate brain tumor cells without harming the eloquent brain.

Entities:  

Keywords:  Adoptive cell therapy; Brain cancer; Cancer vaccines; Clinical trials; Glioma; Immune checkpoint inhibitors; Immune therapy; Oncolytic viruses

Mesh:

Substances:

Year:  2018        PMID: 30311004     DOI: 10.1007/s11864-018-0576-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  96 in total

Review 1.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

2.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Authors:  Duane A Mitchell; Xiuyu Cui; Robert J Schmittling; Luis Sanchez-Perez; David J Snyder; Kendra L Congdon; Gary E Archer; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; John H Sampson
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

4.  Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Authors:  Hideho Okada; Lisa H Butterfield; Ronald L Hamilton; Aki Hoji; Masashi Sakaki; Brian J Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O Lively; Michael D Chan; Andres M Salazar; Edward G Shaw; Douglas M Potter; Frank S Lieberman
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

Review 5.  Immunotherapy Comes of Age in Lung Cancer.

Authors:  Priyanka Khanna; Normand Blais; Pierre-Olivier Gaudreau; Luis Corrales-Rodriguez
Journal:  Clin Lung Cancer       Date:  2016-06-25       Impact factor: 4.785

6.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

7.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.

Authors:  Catherine T Flores; Duane A Mitchell; Tyler J Wildes; Adam Grippin; Kyle A Dyson; Brandon M Wummer; David J Damiani; Rebecca S Abraham
Journal:  Clin Cancer Res       Date:  2018-04-30       Impact factor: 12.531

9.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Authors:  Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-10-29       Impact factor: 12.300

10.  Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.

Authors:  Catherine Flores; Christina Pham; David Snyder; Shicheng Yang; Luis Sanchez-Perez; Elias Sayour; Xiuyu Cui; Hanna Kemeny; Henry Friedman; Darell D Bigner; John Sampson; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

View more
  2 in total

Review 1.  How We Treat Recurrent Glioblastoma Today and Current Evidence.

Authors:  Caroline Chaul-Barbosa; Daniel Fernandes Marques
Journal:  Curr Oncol Rep       Date:  2019-10-12       Impact factor: 5.075

Review 2.  Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Authors:  Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.